645 filings
Page 6 of 33
8-K
ggv42 6rqb2anh
23 Apr 21
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
4:00pm
8-K
z5uh yfu2jtcs
14 Apr 21
Amendments to Articles of Incorporation or Bylaws
11:07am
8-K
yzcz8qad
25 Feb 21
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:04pm
8-K
winthxqj
3 Feb 21
Regulation FD Disclosure
4:16pm
8-K
7spmq03m 2vzq
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
UPLOAD
3r4o3vvfwoq2d7rbvhdt
29 Jan 21
Letter from SEC
12:00am
8-K
yj07vp38fxa73ukgce
28 Jan 21
Departure of Directors or Certain Officers
9:54pm
CORRESP
3ohjlw7gfl3vfb
27 Jan 21
Correspondence with SEC
12:00am
UPLOAD
d8as5
22 Jan 21
Letter from SEC
12:00am
CORRESP
tzv9xmy14er
8 Jan 21
Correspondence with SEC
12:00am
UPLOAD
915veyxv738qd
28 Dec 20
Letter from SEC
12:00am
8-K
u52ypkwkkyv
19 Nov 20
Entry into a Material Definitive Agreement
4:35pm
8-K
x2wrg8rqou0dqzdxwb4
19 Nov 20
Regulation FD Disclosure
11:34am
8-K
4d5yckspm
12 Nov 20
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
4:03pm
8-K
eer2qalgo7n8svp
14 Oct 20
Entry into a Material Definitive Agreement
6:04am
424B5
gy0y8w02vdwpinls
13 Oct 20
Prospectus supplement for primary offering
5:27pm
8-K
fi70f8kug
8 Oct 20
Entry into a Material Definitive Agreement
3:40pm